# Biotech Growth Trust targets small and mid-cap innovation as M&A activity builds

- Link: https://www.directorstalkinterviews.com/biotech-growth-trust-targets-small-and-mid-cap-innovation-as-ma-activity-builds/4121264423
- Published: 2026-10-05T09:26:00+01:00
- Author: Amilia Stone

Biotech Growth Trust is focusing on small and mid-cap biotechnology companies as
its manager identifies valuation opportunities across a sector supported by clinical
innovation, regulatory approvals and pharmaceutical M&A activity.

Jeff Hsu, general partner at OrbiMed and portfolio manager of Biotech Growth Trust
since 2005, said the trust is focused on providing UK investors with access to biotechnology
opportunities globally.

Hsu said the sector is currently supported by several factors, including what he
described as compelling valuations, a favourable regulatory environment and increased
acquisition activity from large pharmaceutical companies. Major pharmaceutical businesses
are facing patent expirations and loss of exclusivity on established blockbuster
medicines, creating a need to replenish their pipelines through acquisitions.

The trust looks for companies with a strong scientific rationale behind their drug
candidates and identifiable catalysts over the following 12 to 18 months. These 
catalysts can include clinical trial results or regulatory decisions from the US
Food and Drug Administration.

Valuation is also a consideration, alongside the quality of management teams and
their ability to execute development plans. For companies that have already demonstrated
proof of concept or generated commercial sales, the potential for an acquisition
is also considered as part of the investment process.

The portfolio is currently weighted towards small and mid-cap biotechnology companies.
Hsu said this reflects the concentration of innovation in these parts of the market,
with around two-thirds of innovation in the biopharmaceutical industry taking place
among small and mid-cap companies, according to his assessment.

The focus also reflects valuations, with Hsu saying the trust is finding some of
its most compelling opportunities among smaller companies.

M&A has become an increasingly relevant part of the sector. Hsu said the trust has
held several companies that were subsequently acquired, allowing shareholders to
benefit from transactions involving portfolio holdings. He expects pharmaceutical
M&A activity to remain strong through the rest of the year, with patent expirations
continuing to create pressure on large drug companies to find replacement sources
of revenue.

_**Biotech Growth Trust plc** (LON:BIOG) seeks capital appreciation through investment
in the worldwide biotechnology industry. The Company and the Company’s Portfolio
Manager believe that there is a high congruence between companies that seek to act
responsibly and those that succeed in building long-term shareholder value. _

Share on:
